Jane Street’s ProShares UltraPro Short NASDAQ Biotechnology ZBIO Stock Holding History

Jane Street’s Portfolio ZBIO Stock Details ZBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-11,700	Closed	-$155K	–	6074
2019 Q1	$155K	Hold	11,700	–	–	﹤0.01%	4710
2018 Q4	$257K	Buy	+11,700	New	+$215K	﹤0.01%	4236
2018 Q3	–	Sell	-17,550	Closed	-$317K	–	6003
2018 Q2	$317K	Buy	+17,550	New	+$354K	﹤0.01%	4059
2018 Q1	–	Sell	-7,350	Closed	-$168K	–	5709
2017 Q4	$168K	Sell	7,350 -7,100	-49%	-$165K	﹤0.01%	4260
2017 Q3	$301K	Sell	14,450 -3,700	-20%	-$88.7K	﹤0.01%	3686
2017 Q2	$487K	Buy	+18,150	New	+$588K	﹤0.01%	3073
2016 Q4	–	Sell	-55,500	Closed	-$2.35M	–	4843
2016 Q3	$2.35M	Buy	55,500 +20,000	+56%	+$924K	0.01%	1067
2016 Q2	$2.3M	Buy	+35,500	New	+$2.18M	0.01%	1151

Other funds holding ZBIO

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cutler Group San Francisco, California $307M AUM 45.11% 1-Year Est. Return

Jane Street's ZBIO Position: Q2 2019 in Review

Jane Street sold out of ProShares UltraPro Short NASDAQ Biotechnology (ZBIO) in Q2 2019, closing a stake of 13,247 shares — an estimated $176K sold.

Jane Street first reported a position in ZBIO in Q3 2015 and held it in 11 quarters. The position peaked at $769K in Q1 2016. 5 funds tracked by Wall St. Rank hold ZBIO as of Q2 2019.

Jane Street reported no remaining ProShares UltraPro Short NASDAQ Biotechnology position as of Q2 2019 after selling out during the quarter.
Jane Street sold 13,247 ProShares UltraPro Short NASDAQ Biotechnology shares in Q2 2019, an estimated $176K.
Jane Street first reported a position in ProShares UltraPro Short NASDAQ Biotechnology in Q3 2015 and held it in 11 quarters.
Jane Street's ProShares UltraPro Short NASDAQ Biotechnology position peaked at $769K in Q1 2016.
5 funds tracked by Wall St. Rank held ProShares UltraPro Short NASDAQ Biotechnology as of Q2 2019.

Based on Jane Street's 13F filing for Q2 2019, filed 15 Aug 2019.